The effect of long term low dose erythromycin on cough frequency in chronic unexplained cough: a randomised, double blind, placebo conrolled, parallel group trial - macrolides in chronic cough

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2007-000750-31-GB

Enrollment

Registered

2008-03-18

Start date

2007-10-16

Completion date

Unknown

Last updated

2019-11-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic unexplained cough

Interventions

Trade Name: erythrocin 250 Pharmaceutical Form: Film-coated tablet Pharmaceutical form of the placebo: Capsule* Route of administration of the placebo:

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Cough lasting greater than 8 weeks which remains unexplained after routine clinical assessment as outlined in the British Thoracic Society Cough guidelines document. Normal spirometry values Normal methocholine challange test Normal sputum eosinophillia No response to a 3 month trial of a high dose PPI No response to a trial of a nasal steriod Normal CT thorax Non smokers with a less than 10 pack year smoking history Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Intolerance to macrolides Pregnant Breastfeeding Unable to consent

Design outcomes

Primary

Measure	Time frame
Main Objective: To investigate the effect of long term low dose erythromycin on objective and subjective markers of cough in chronic unexplained cough;Secondary Objective: Determine which radiological and inflammatroy features of cough makes it more likely to respond to erythromycin.;Primary end point(s): cough frequency before, during, at the end of and 3 months following treatment with a macrolide antibiotic.	—

Measure

Time frame

Main Objective: To investigate the effect of long term low dose erythromycin on objective and subjective markers of cough in chronic unexplained cough;Secondary Objective: Determine which radiological and inflammatroy features of cough makes it more likely to respond to erythromycin.;Primary end point(s): cough frequency before, during, at the end of and 3 months following treatment with a macrolide antibiotic.

—

Countries

United Kingdom

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026